| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:55 UTC |
|---|
| HMDB ID | HMDB0015258 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Dutasteride |
|---|
| Description | Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia ] |
|---|
| Structure | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | ChEBI | | alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide | ChEBI | | Avodart | Kegg | | (5a,17b)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | Generator | | (5Α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide | Generator | | a,a,a,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5a-androst-1-ene-17b-carboxy-2',5'-xylidide | Generator | | Α,α,α,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidide | Generator | | 17beta-N-(2,5-Bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one | HMDB | | 745, GG | HMDB |
|
|---|
| Chemical Formula | C27H30F6N2O2 |
|---|
| Average Molecular Weight | 528.5297 |
|---|
| Monoisotopic Molecular Weight | 528.221147444 |
|---|
| IUPAC Name | (1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-14-carboxamide |
|---|
| Traditional Name | dutasteride |
|---|
| CAS Registry Number | 164656-23-9 |
|---|
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F |
|---|
| InChI Identifier | InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1 |
|---|
| InChI Key | JWJOTENAMICLJG-QWBYCMEYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-oxosteroid
- 3-oxo-4-azasteroid
- 3-oxo-5-alpha-steroid
- Oxosteroid
- 4-azasteroid
- Azasteroid
- Trifluoromethylbenzene
- Anilide
- N-arylamide
- Monocyclic benzene moiety
- Benzenoid
- Carboxamide group
- Lactam
- Secondary carboxylic acid amide
- Azacycle
- Carboxylic acid derivative
- Organoheterocyclic compound
- Organohalogen compound
- Alkyl halide
- Alkyl fluoride
- Organic nitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Organofluoride
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.00091 g/L | Not Available | | LogP | 6.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.07 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 21.9426 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.54 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3743.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 519.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 262.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 231.6 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 670.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 1030.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 1072.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 88.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1862.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 721.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2001.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 584.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 589.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 191.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 203.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Dutasteride,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3284.2 | Semi standard non polar | 33892256 | | Dutasteride,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3296.4 | Standard non polar | 33892256 | | Dutasteride,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3763.8 | Standard polar | 33892256 | | Dutasteride,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3261.8 | Semi standard non polar | 33892256 | | Dutasteride,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3291.2 | Standard non polar | 33892256 | | Dutasteride,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3820.7 | Standard polar | 33892256 | | Dutasteride,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3188.4 | Semi standard non polar | 33892256 | | Dutasteride,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3383.5 | Standard non polar | 33892256 | | Dutasteride,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C | 3553.0 | Standard polar | 33892256 | | Dutasteride,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]12 | 3490.9 | Semi standard non polar | 33892256 | | Dutasteride,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]12 | 3483.3 | Standard non polar | 33892256 | | Dutasteride,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]12 | 3841.1 | Standard polar | 33892256 | | Dutasteride,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3463.5 | Semi standard non polar | 33892256 | | Dutasteride,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3483.4 | Standard non polar | 33892256 | | Dutasteride,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3881.9 | Standard polar | 33892256 | | Dutasteride,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3548.1 | Semi standard non polar | 33892256 | | Dutasteride,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3747.9 | Standard non polar | 33892256 | | Dutasteride,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F | 3673.9 | Standard polar | 33892256 |
|
|---|